2024年血制品行业跟踪报告（附批签发）：全年人白批次增长14%，价格开始调整

Investment Rating - The report suggests a focus on key companies in the blood products industry, including Shanghai RAAS (002252.SZ), Tian Tan Bio (600161.SH), Weigao Bio (002880.SZ), Hualan Bio (002007.SZ), Palin Bio (000403.SZ), and Boya Bio (300294.SZ) [3] Core Insights - The blood products industry experienced a 14% increase in human albumin batch approvals in 2024, with domestic approvals growing by 9% and imports by 17% [3][8] - Immunoglobulin approvals saw a 3% increase, while specific products like rabies immunoglobulin and tetanus immunoglobulin grew by 24% and 12% respectively [8][46] - The net profit growth for blood product companies was 12% in the first three quarters of 2024, with total revenue reaching approximately 17.6 billion yuan, a 1.7% increase [3] Batch Approval Summary - Human Albumin: In 2024, total batch approvals reached 5,423 (+14%), with domestic approvals at 1,708 (+9%) and imports at 3,715 (+17%) [3][15] - Immunoglobulin: Total approvals for intravenous immunoglobulin were 1,308 (+3%), with Q4 showing a significant increase of 39% [3][38] - Coagulation Factors: Coagulation factor VIII approvals increased by 33% to 568 batches, while prothrombin complex concentrate (PCC) saw a decrease of 18% [3][69] - Rabies Immunoglobulin: Total approvals reached 148 batches, marking a 24% increase [46][56] - Tetanus Immunoglobulin: Total approvals were 145 batches, reflecting a 12% increase [58][67]